PPARA and neoplasm: This experimental evidence demonstrated the direct involvement of PPARα in GCs tumor resistance, since it is upregulated by DEX and is a well-known FAO regulator; in addition, PPARα antagonists revoked these effects and sensitized CLL cells to DEX [117].